SynthesisCurrent oncology (Toronto, Ont.)2023

Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis.

Alessandro Rizzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.